Skip to main content

Test Price

2,800 AED

✅ Home Collection Available

UAE PREMIER GENOMIC SCREEN

BMP1 Gene Osteogenesis Imperfecta Type 13 Genetic Test in UAE

2,800 AED · DHA 2026 Clinical Genetic Guidelines

تحليل جين BMP1 للكشف عن تكون العظم الناقص النوع 13 الجيني في الإمارات | 2,800 درهم | معتمد من هيئة الصحة بدبي

الملخص التنفيذي: فحص جيني متطور بتقنية التسلسل عالي الإنتاجية (NGS) لتحليل التغيرات المُمْرِضة في جين BMP1. يوفر هذا التحليل تأكيداً تشخيصياً دقيقاً لحالة تكون العظم الناقص من النوع الثالث عشر، مع خدمة سحب منزلي معقمة ونتائج شاملة تدعم اتخاذ القرارات العلاجية المبنية على الأدلة وفقاً لأعلى معايير هيئة الصحة بدبي والامتثال الفيدرالي.

  • 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).
  • Premium Logistics: Hospital-Grade Home Collection via ISO-Certified Cold-Chain & VIP Mobile Phlebotomy (8 AM - 11 PM).
  • Clinical Guidance: Telephonic Post-Test Interpretation by certified molecular geneticists.
  • Insurance Support: Direct Billing Verification via WhatsApp +971 54 548 8731.

Comprehensive Genomic Analysis Overview

This Next-Generation Sequencing (NGS) panel comprehensively screens the BMP1 gene for pathogenic variants associated with Osteogenesis Imperfecta Type 13, a severe connective tissue disorder distinguished by recurrent fractures and bone fragility. In parallel, يقدم هذا الفحص الجيني المتقدم تحديداً دقيقاً للطفرات المسببة لأنواع هشة العظام الوراثية ensuring differential diagnosis from other osteology-dermatology-immunology disorders.

Feature Our Genomic Test Closest Alternative (Single Gene Sanger)
Precision 99.9% Analytical Sensitivity via LC-MS/MS validated NGS Moderate; restricted to targeted exons only
Method NGS with CNV & Intronic Splice Site Analysis Bidirectional Sanger Sequencing
Speed (TAT) 3 to 4 Weeks with Interim Clinical Reports 6 to 8 Weeks

*Comparison for educational purposes. All follow 2026 DHA/MOHAP Nomenclature.

Physician Insight & Safety Protocol

“Genetic diagnosis for Osteogenesis Imperfecta Type 13 requires careful clinical correlation; this NGS test provides definitive molecular classification to differentiate it from other collagenopathies, enabling precise prognosis and family planning. Any result must be interpreted within the full context of the patient’s fracture history and multisystem involvement.”

— Dr. PRABHAKAR REDDY (DHA Lic. 61713011), Specialist in Clinical Genomics

⚠ Critical Medication Warning

Do not discontinue any prescribed bisphosphonate therapy, calcium, or vitamin D supplementation without explicit consultation with your managing physician. Genetic results do not replace acute clinical fracture management.

Exclusion Criteria & Emergency Red Flags

  • Specimen Rejection: Clotted blood samples, non-sterile FTA cards, or samples without dual patient-physician identifier labeling.
  • Administrative Lock: CDS Law 2026 Compliance: Mandatory notarized guardian consent for minors; unaccompanied minors cannot undergo phlebotomy.
  • URGENT: Seek immediate emergency care for sudden vision loss, acute hearing loss, or basilar skull fracture symptoms independent of genetic testing timelines.

Patient FAQ & Clinical Guidance

Q: What specific mutations does the BMP1 NGS test identify, and how does it compare to standard bone density scans?

This comprehensive NGS assay identifies single nucleotide variants, small insertions/deletions, and copy number changes throughout the entire BMP1 coding region, providing molecular confirmation that standard DEXA bone densitometry cannot offer for differentiating genetic fragility types. يحدد هذا الاختبار الطفرات الجينية المسببة للمرض بدقة لا توفرها فحوصات كثافة العظام التقليدية.

Q: Why is a 3 to 4 week turnaround required for BMP1 analysis when other blood tests are faster?

The extended TAT accommodates the complex bioinformatics pipeline required for high-fidelity NGS, including library preparation, iterative alignment against the GRCh38 reference genome, and multi-disciplinary variant classification by molecular pathologists before final sign-out. تستغرق العملية فترة أطول لضمان تحليل المعلوماتية الحيوية الدقيق وتصنيف الطفرات من قبل خبراء الوراثة.

Q: Can I use an FTA card collected at home for this specific NGS to avoid a clinic visit?

Yes, a single drop of blood properly applied to a sterile DNA FTA card by our DHA-licensed VIP mobile phlebotomist during the home visit is a fully validated sample type, ensuring DNA stability during ambient temperature cold-chain transport to the sequencing facility. نعم، يمكن استخدام بطاقة FTA المعقمة لجمع العينة منزلياً بواسطة اختصاصي سحب مرخص، بشرط الالتزام ببروتوكول السلسلة الباردة.

دعم ثنائي اللغة متاح

التحقق من التغطية التأمينية

Check Insurance Coverage Instantly

Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.

توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.

✅ DHA Certified ✅ ISO 15189 ✅ HIPAA Compliant

Available in Arabic, English, Hindi & Urdu

🏅

ISMS 27001:2022

📋

ISO Accredited

🔒

HIPAA

All reports reviewed by DHA-Certified physicians